ENDRA Life Sciences (NASDAQ:NDRA) reported its Q4 earnings results on Wednesday, March 30, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
ENDRA Life Sciences reported in-line EPS of $-0.08 versus an estimate of $-0.08.
ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the Chinese National Intellectual Property Administration has issued ENDRA two new patents,
ENDRA Life Sciences (NASDAQ:NDRA) is set to give its latest quarterly earnings report on Wednesday, 2022-03-30. Here's what investors need to know before the announcement.
Analysts estimate that ENDRA Life Sciences will report an earnings per share (EPS) of $-0.08.
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.
Gainers
CVRx (NASDAQ:CVRX) shares rose 11.6% to $7.2 during Friday's after-market session. The market value of their outstanding shares is at $156.2 million.
ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the United States Patent and Trademark Office has issued ENDRA a new patent, U.S. Patent No. 11266314